SonoVascular, Inc.
Craig Nichols currently serves as the Vice President of Clinical and RA/QA at SonoVascular, Inc. since September 2022, previously holding the Director of Technical Operations title. Prior experience includes multiple roles at InnAVasc Medical, Inc. from July 2017 to August 2022, culminating as Director of Product Development & Regulatory Affairs, along with positions as Senior Development Engineer. Craig's career began at Stanford University as a Biodesign Innovation Fellow, focusing on innovative healthcare solutions. Additionally, Craig served as a Biomedical Engineer with the FDA from October 2011 to March 2016, leading evaluations of cardiovascular devices and enhancing knowledge management practices within the agency. Earlier roles include research internships and assistantships, complemented by a Bachelor of Science in Applied Sciences from the University of North Carolina at Chapel Hill.
This person is not in any teams
SonoVascular, Inc.
SonoVascular has developed a novel pharmaco-mechanical ultrasound facilitated thrombectomy system, SonoThrombectomy™, that utilizes microbubble-mediated cavitation as a core enabling mechanism of action to remove blood clots more effectively. The system uniquely combines: (i) ultrasound, (ii) microbubbles, (iii) low dose thrombolytic drug, and (iv) mechanical retrieval and aspiration, delivered via an integrated intravascular catheter system. SonoVascular’s technology has been engineered to address and overcome the deficiencies and limitations of current interventional devices. Its design enables safe and effective treatment in the catheterization laboratory (cathlab), maximizes the reduction in clot burden, enhances the delivery and reduces the dose and duration of thrombolytics to levels that optimize safety and effectiveness, and eliminates the need for patients to be treated in the ICU.